Advertisement
Table 4 Changes in ITSQ and PAM-D21 questionnaire scores
| Variable, change from baseline | LM25 (N = 80) | IGL (N = 82) | ||
|---|---|---|---|---|
| Baseline | Change from baseline | Baseline | Change from baseline | |
| ITSQ, mean (SD) | ||||
| Inconvenience of regimen | 92.7 (10.7) | −1.5 (11.0) | 92.2 (12.1) | 0.5 (11.2) |
| Lifestyle flexibility | 82.9 (21.2) | −0.1 (24.1) | 84.7 (17.6) | −4.8 (24.9) |
| Glycemic control | 80.9 (19.9) | 6.9 (20.0) | 78.3 (21.7) | 10.3 (22.1) |
| Hypoglycemic control | 85.5 (14.7) | −2.7 (17.7) | 85.7 (17.8) | 0.1 (17.0) |
| Insulin delivery device satisfaction | 86.9 (15.7) | 4.2 (16.1) | 88.6 (14.3) | 1.1 (10.6) |
| Total score | 86.5 (11.4) | 1.1 (11.6) | 86.8 (12.4) | 1.2 (10.6) |
| PAM-D21, mean (SD) | ||||
| Convenience/flexibility | 90.0 (16.0) | −0.7 (21.2) | 91.7 (13.8) | −1.2 (16.8) |
| Perceived effectiveness | 74.6 (20.7) | 5.9 (23.7) | 72.0 (20.5) | 12.0 (25.4) |
| Emotional effects | 84.2 (20.2) | 1.0 (21.7) | 86.8 (17.5) | −0.2 (22.4) |
| Physical effects | 87.0 (13.4) | 1.0 (12.8) | 90.5 (12.9) | 1.1 (10.4) |
